

Group III, claim(s) 1 in part, 25 and 26, drawn to a composition comprising a molecule that inhibits nuclear envelope breakdown wherein the molecule is a small molecule.

Group IV, claim(s) 1 in part, and 27 drawn to a composition comprising a molecule that inhibits nuclear envelope breakdown wherein the molecule is an aptamer.

Group V, claim(s) 28, drawn to a method of identifying compound that inhibits nuclear envelope breakdown by assaying Nup153/COPI complex formation.

Group VI, claim(s) 34 and 40, drawn to a method of identify and producing a compound.

Group VII, claim(s) 46, drawn to method of producing an antibody.

Group VIII, claim(s) 49, drawn to method of using an antibody.

Group IX, claim(s) 50, drawn to method of inhibiting cell cycle.

Group X, claim(s) 51, drawn to method of identifying proteins that interact with Nup153 by assaying expression of reporter protein.

Group XI, claim(s) 53, drawn to a system for assaying nuclear breakdown.

Group XII, claim(s) 57, drawn to a method of detecting expression of Nup153.

Group XIII, claim(s) 59, drawn to method of inhibiting nuclear envelope breakdown.

Group XIV, claim(s) 62, drawn to method of treatment.

In response, applicants elect Group IX, claim 50, drawn to a method of inhibiting a cell cycle, with traverse.

**ATTORNEY DOCKET NO. 21101.0045U2**  
**Application No. 10/528,183**

37 C.F.R. § 1.475 provides that national stage applications shall relate to one invention or to a group of inventions so linked as to form a single general inventive concept. Such inventions possess unity of invention. The requirement of a single inventive concept is fulfilled when there is a technical relationship within the claimed subject matter involving one or more of the same or corresponding special technical features. Applicants respectfully request that the entire restriction requirement be reconsidered, and in particular claims 28, 34, 51, 53, 57 and 62. It is the applicant's contention that claims 28, 34, 50, 51, 53, 57, and 62 relate to a single general inventive concept, as all of these claims deal with inhibiting Nup153.

To be valid, a restriction requirement must establish both that (1) the "inventions" are either independent or distinct, and (2) that examination of more than one of the "inventions" would constitute a burden to the Examiner. Applicants note that the restriction/election requirement does not provide sufficient basis to indicate that examination of more than one of the "inventions" would overly burden the Examiner.

It should be noted that Groups X-XI, IX-XII, and XIV are all related to Nup153 inhibition as it relates to nuclear breakdown, and methods of using this compound. The Examiner states that no special technical feature runs through the respective groups in which to unify them. However, the special technical feature of each of these groups is that Nup153 is used to identify compounds and to treat disease. This was not previously known in the art, and represents a common special technical feature present in each of X-XI, IX-XII, and XIV. Applicants therefore request reconsideration of the restriction.

An EFS Web Credit Card Payment authorizing payment in the amount of \$1,115.00 representing the fee for a small entity under 37 C.F.R. § 1.17(a)(1), and a Request for Extension